Guardant Health, Inc. (GH) income statement
NASDAQ · Healthcare · Medical - Diagnostics & Research · 2,498 employees · CEO Helmy Eltoukhy
- Price
- $145.83 +0.16%
- Market cap
- $19.7B
- Enterprise value
- $20.4B Data as of 2026-11-22
- Last report
- Q3 '26 filed 2026-11-05
- Next report
- 2027-02-18 EPS est. -$0.75
Guardant Health, Inc. (GH) reported revenue of $361M for Q3 '26 (+36.1% year on year), operating income of -$133M (-36.8% of revenue) and net income of -$124M. Over the last four quarters revenue was $1.28B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $155M | $168M | $177M | $191M | $202M | $203M | $232M | $265M | $281M | $302M | $335M | $361M | |
| Cost of revenue | $62.5M | $65.3M | $72.4M | $74.5M | $77.6M | $74.7M | $81.2M | $93.6M | $99.5M | $105M | $116M | $125M | |
| Gross profit | $92.5M | $103M | $105M | $117M | $124M | $129M | $151M | $172M | $182M | $197M | $219M | $236M | |
| Research & development | $89.9M | $83.8M | $83.1M | $87.3M | $93.5M | $88.5M | $87.4M | $90M | $98.3M | $91M | $96.5M | $101M | |
| Sales & marketing | $79.1M | $80.4M | $81.9M | $97.9M | $105M | $104M | $120M | $127M | $143M | $169M | $190M | $177M | |
| General & administrative | $37.7M | $38.7M | $40.5M | $49.1M | $51.9M | $47M | $50.3M | $53.3M | $60.9M | $57.9M | $61.7M | $90.9M | |
| Other operating expenses | $83.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating expenses | $290M | $203M | $205M | $234M | $250M | $240M | $257M | $271M | $303M | $318M | $348M | $369M | |
| Operating income | -$198M | -$99.7M | -$101M | -$117M | -$126M | -$111M | -$106M | -$99M | -$121M | -$121M | -$129M | -$133M | |
| Interest income | $13.9M | $14.9M | $13.9M | $13.3M | $11.7M | $9.11M | $7.56M | $7.39M | $10M | $11.2M | $10.2M | $9.75M | |
| Interest expense | $645K | $645K | $645K | $646K | $645K | $791K | $983K | $943K | $1.18M | $1.35M | $1.35M | $1.35M | |
| Other non-operating income (gains on investments, FX ...) | -$10.6M | $14.3M | $1.23M | -$10.3M | -$16.3M | -$17M | -$7.54M | -$7.34M | $8.24M | -$11M | -$10.5M | -$10.1M | |
| Total non-operating income | $9.93M | -$14.9M | -$1.88M | $9.6M | $15.7M | $16.2M | $6.55M | $6.4M | -$9.42M | $9.65M | $9.16M | $8.75M | |
| Income before tax | -$188M | -$115M | -$102M | -$108M | -$110M | -$94.9M | -$99.9M | -$92.6M | -$130M | -$112M | -$120M | -$124M | |
| Income tax | -$541K | $405K | $133K | $30K | $716K | $290K | $38K | $136K | -$1.73M | $372K | $185K | $343K | |
| Net income | -$187M | -$115M | -$103M | -$108M | -$111M | -$95.2M | -$99.9M | -$92.7M | -$128M | -$112M | -$120M | -$124M | |
| EPS (basic) | -$1.58 | -$0.94 | -$0.84 | -$0.88 | -$0.90 | -$0.77 | -$0.80 | -$0.74 | -$1.00 | -$0.85 | -$0.90 | -$0.93 | |
| EPS (diluted) | -$1.58 | -$0.94 | -$0.84 | -$0.88 | -$0.90 | -$0.77 | -$0.80 | -$0.74 | -$1.00 | -$0.85 | -$0.90 | -$0.93 | |
| Shares (basic, weighted) | 119M | 122M | 122M | 123M | 124M | 124M | 124M | 125M | 129M | 131M | 132M | 134M | |
| Shares (diluted, weighted) | 119M | 122M | 122M | 123M | 124M | 124M | 124M | 125M | 129M | 131M | 132M | 134M | |
| Depreciation & amortization | $10.9M | $10.7M | $10.6M | $10.6M | $10.5M | $10.2M | $10M | $9.41M | $10.1M | $9.44M | $9.56M | $10.2M | |
| EBITDA | -$176M | -$103M | -$91.2M | -$96.5M | -$99.2M | -$83.8M | -$88.8M | -$82.2M | -$119M | -$101M | -$109M | -$112M |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.2M | $49.8M | $90.6M | $214M | $287M | $374M | $450M | $564M | $739M | $982M | |
| Cost of revenue | $22.1M | $31.6M | $43.2M | $70.7M | $92.5M | $123M | $156M | $227M | $290M | $349M | |
| Gross profit | $3.13M | $18.2M | $47.4M | $144M | $194M | $251M | $293M | $337M | $449M | $633M | |
| Research & development | $10.9M | $25.6M | $50.7M | $86.3M | $150M | $263M | $374M | $367M | $348M | $364M | |
| Sales & marketing | $26.2M | $32.5M | $53.5M | $78.3M | $107M | $192M | $300M | $295M | $365M | $495M | |
| General & administrative | $9.92M | $36.8M | $36.2M | $61.4M | $193M | $207M | $164M | $156M | $180M | $211M | |
| Other operating expenses | -$1K | $0 | $0 | $88K | $0 | $0 | $0 | $83.4M | $0 | $0 | |
| Operating expenses | $47M | $94.8M | $140M | $226M | $449M | $662M | $838M | $902M | $893M | $1.07B | |
| Operating income | -$43.8M | -$76.6M | -$92.9M | -$82.4M | -$255M | -$411M | -$544M | -$565M | -$444M | -$437M | |
| Interest income | $733K | $2.23M | $5.27M | $13.7M | $10.2M | $3.93M | $6.07M | $35.4M | $53.7M | $34.1M | |
| Interest expense | $3.02M | $2.7M | $1.25M | $1.18M | $4.77M | $2.58M | $2.58M | $2.58M | $2.58M | $3.9M | |
| Other non-operating income (gains on investments, FX ...) | -$732K | $3.9M | -$9.97M | -$13.8M | -$13.8M | -$29.1M | $106M | -$88.5M | -$11.1M | -$23.6M | |
| Total non-operating income | -$2.29M | -$6.6M | $8.72M | $12.6M | $9.05M | $26.5M | -$109M | $86M | $8.51M | $19.7M | |
| Income before tax | -$46.1M | -$83.2M | -$84.2M | -$69.7M | -$246M | -$384M | -$653M | -$479M | -$435M | -$418M | |
| Income tax | $6K | $7K | $38K | -$1.87M | $379K | $300K | $1.14M | $685K | $1.28M | -$1.26M | |
| Net income | -$46.1M | -$83.2M | -$85.1M | -$75.7M | -$254M | -$406M | -$655M | -$479M | -$436M | -$416M | |
| EPS (basic) | -$3.49 | -$1.18 | -$1.00 | -$0.75 | -$2.53 | -$4.00 | -$6.41 | -$4.28 | -$3.56 | -$3.32 | |
| EPS (diluted) | -$3.49 | -$1.18 | -$1.00 | -$0.75 | -$2.53 | -$4.00 | -$6.41 | -$4.28 | -$3.56 | -$3.32 | |
| Shares (basic, weighted) | 13.2M | 70.7M | 85M | 90.6M | 97.5M | 101M | 102M | 112M | 123M | 125M | |
| Shares (diluted, weighted) | 13.2M | 70.7M | 85M | 90.6M | 97.5M | 101M | 102M | 112M | 123M | 125M | |
| Depreciation & amortization | $3.69M | $5.21M | $7.14M | $11.4M | $16.1M | $22.3M | $36M | $42.9M | $42.4M | $39.7M | |
| EBITDA | -$39.4M | -$75.3M | -$75.8M | -$57.1M | -$225M | -$360M | -$615M | -$433M | -$390M | -$374M |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-22